2.2 C
New York
Wednesday, February 1, 2023

Athira Pharma Inc. (NASDAQ: ATHA) Could Be Viewed Differently By Investors Because Of These Numbers

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Athira Pharma Inc. (ATHA) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.21, or 5.75%, to $3.86. The Athira Pharma Inc. has recorded 9,322 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Athira Pharma Provides 2023 Pipeline Outlook.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Stocks Info

The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $3.65 and fluctuated between $3.8650 as its day high and $3.4300 as its day low. The current market capitalization of Athira Pharma Inc. is $133.33M. A total of 0.76 million shares were traded on the day, compared to an average of 307.09K shares.

Insider Activity

Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, ATHA has seen 3 BUY and 0 SELL insider trades, representing the acquisition of 38,700 and the disposition of 0 shares. Over the last 12 months, there were 22 BUYs and 5 SELLs from insiders. Insiders purchased 1,522,411 shares during that period but sold 19,995.

In the most recent transaction, MILESON GLENNA bought 50,000 shares of ATHA for 2.85 per share on Dec 28. After the transaction, the Chief Financial Officer now owns 159,930 company shares. In a previous transaction on Dec 02, Romano Kelly A bought 30,000 shares at 3.29 per share. ATHA shares that Director owns now total 38,315.

Among the insiders who bought shares, MOEBIUS HANS acquired of 5,000 shares on Nov 15 at a per-share price of $3.29. This resulted in the Chief Medical Officer holding 65,836 shares of ATHA after the transaction. In another insider transaction, PERCEPTIVE ADVISORS LLC bought 1,101,362 shares at $2.99 per share on Jun 30. Company shares held by the Director now total 4,797,278.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for ATHA in the last 3 months, the mean price target is $11.75 with high estimates of $33.00 and low estimates of $3.00. In terms of 52-week highs and lows, ATHA has a high of $14.22 and a low of $2.53.

As of this writing, ATHA has an earnings estimate of -$0.63 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.57 per share and a lower estimate of -$0.69. The company reported an EPS of -$0.56 in the last quarter, which was -1.80% lower than expectations of -$0.55.

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ATHA is Overweight with a score of 4.33. A total of 3 analysts rated the stock as Buy while 0 rated it as Overweight while 3 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles